Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 24;220(4):687–698. doi: 10.1093/infdis/jiy740

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 6. — Predicted metagenomic capacity at KEGG pathway level reveals no significant different pathway. Metagenomic capacity was predicted using Piphillin. (A) Heat map depicts the relative abundance of top 20 KEGG pathway before and after malaria episode/artemether-lumefantrine (AL) treatment and (B) the log₂-fold change (log2FC) of these pathways. (C) KEGG pathways were normalized with DeSeq2, and differentially abundant pathways were analyzed with DeSeq2 and t test (P < .05) and (D) fold change (FC) of pathways common to both methods. (E) Relative abundance of N-glycan biosynthesis pathway having highest fold change. Data were analyzed by linear mixed-effects model. A, after malaria sample; B, before malaria sample.